Skip to main content
. 2023 Dec 9;39(12):btad743. doi: 10.1093/bioinformatics/btad743

Table 3.

Comparison to previous methods.a

TPP2 AUROC TPP2 AP TPP3 AUROC TPP3 AP
EPIC-TRACE (our) [Dαβ,α,β] 0.906 ± 0.000 0.691 ± 0.001 0.693 ± 0.008 0.294 ± 0.007
EPIC-TRACE (our) 0.906 ± 0.000 0.698 ± 0.000 0.691 ± 0.008 0.291 ± 0.005
ERGO-II 0.895 ± 0.002 0.659 ± 0.007 0.675 ± 0.007 0.274 ± 0.004
epiTCR 0.793 ± 0.000 0.581 ± 0.000 0.515 ± 0.001 0.183 ± 0.001
TITAN 0.786 0.454 0.577 0.204
ImRex 0.697 0.420 0.519 0.178
a

EPIC-TRACE, ERGO-II, and epiTCR are evaluated on five 10-fold cross-validation runs, whereas TITAN and ImRex are evaluated on only one of the five cross-validations due to long training time. Reported values are the mean of the five 10-fold cross-validation runs together with the standard error. Values for best performing models are bolded.